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Stable coronary syndromes: pathophysiology, 
diagnostic advances and therapeutic need
Thomas J Ford,1,2,3 David Corcoran,1,2,4 Colin Berry1,2,4
AbStrAct
The diagnostic management of patients with angina 
pectoris typically centres on the detection of obstructive 
epicardial CAD, which aligns with evidence-based 
treatment options that include medical therapy and 
myocardial revascularisation. This clinical paradigm 
fails to account for the considerable proportion 
(approximately one-third) of patients with angina 
in whom obstructive CAD is excluded. This common 
scenario presents a diagnostic conundrum whereby 
angina occurs but there is no obstructive CAD (ischaemia 
and no obstructive coronary artery disease—INOCA). We 
review new insights into the pathophysiology of angina 
whereby myocardial ischaemia results from a deficient 
supply of oxygenated blood to the myocardium, due 
to various combinations of focal or diffuse epicardial 
disease (macrovascular), microvascular dysfunction or 
both. Macrovascular disease may be due to the presence 
of obstructive CAD secondary to atherosclerosis, or may 
be dynamic due to a functional disorder (eg, coronary 
artery spasm, myocardial bridging). Pathophysiology of 
coronary microvascular disease may involve anatomical 
abnormalities resulting in increased coronary resistance, 
or functional abnormalities resulting in abnormal 
vasomotor tone. We consider novel clinical diagnostic 
techniques enabling new insights into the causes of 
angina and appraise the need for improved therapeutic 
options for patients with INOCA. We conclude that the 
taxonomy of stable CAD could improve to better reflect 
the heterogeneous pathophysiology of the coronary 
circulation. We propose the term ’stable coronary 
syndromes’ (SCS), which aligns with the well-established 
terminology for ’acute coronary syndromes’. SCS 
subtends a clinically relevant classification that more fully 
encompasses the different diseases of the epicardial and 
microvascular coronary circulation. 
IntroductIon
Ischaemic heart disease (IHD) persists as the 
leading global cause of death and lost life years 
in adults.1 Reductions in morbidity and mortality 
are not consistent across subgroups, with mortality 
being persistently high in younger women.2 
Overall, stable ischaemic heart disease (SIHD) 
remains a worldwide public health problem of 
unmet need.
Stable coronary artery disease (CAD), or SIHD, 
refers to the syndrome of recurrent, transient 
episodes of chest pain reflecting demand-supply 
mismatch, that is, angina pectoris. In this article, 
we reappraise the causes of angina based on new 
insights into coronary pathophysiology. We focus 
on disorders of coronary artery function and their 
clinical relevance.
taxonomy
Given the unmet need of IHD, recent advances in 
diagnostics and the need for further improvements 
in primary and secondary prevention, we propose 
the term ‘stable coronary syndromes’ (SCS) to 
succinctly reflect the heterogeneous pathophysi-
ology of epicardial, microvascular and endothe-
lial abnormalities in patients with stable angina. 
SCS aligns with terminology for acute coronary 
syndromes, and helps to standardise the hierarchy 
of IHD endotypes, including ischaemia with no 
obstructive coronary artery disease (INOCA)3 and 
myocardial infarction with no obstructive CAD 
(figure 1).
the clinical conundrum of angina
Classically, angina is considered to be due to 
flow-limiting CAD,4 which by definition results in 
a supply-demand mismatch in myocardial perfu-
sion. Anatomical thresholds for CAD severity 
vary. A widely used cut-off for obstructive CAD 
is taken as a stenosis of 70% in a main coronary 
artery (>2.5 mm) in one angiographic projection, 
or 50% in two projections, and 50% of the left 
main coronary artery.5 The management of patients 
with angina appropriately centres on the detection 
of obstructive epicardial CAD, which may be chal-
lenging to diagnose objectively ( e. g. mild tandem 
lesions in series may cause flow-limiting disease). 
Systemic problems including anaemia and aortic 
stenosis also influence the propensity to angina and 
should be considered. In patients with obstructive 
epicardial CAD, the treatment involves optimal 
medical therapy and consideration of myocardial 
revascularisation with either percutaneous coro-
nary intervention (PCI) or coronary artery bypass 
grafting (CABG). However, this paradigm fails 
to account for one-third or more patients with 
angina in whom obstructive CAD is excluded. A US 
registry of 398 978 patients referred for coronary 
angiography demonstrated that 39.2% of patients 
had no evidence of epicardial CAD.6 Also, angina 
may persist following PCI and CABG. The reasons 
for ‘negative’ coronary angiography are multifacto-
rial. However, a growing body of evidence supports 
the use of coronary function tests, especially since 
a disorder of coronary artery function may be the 
unifying diagnosis in a patient with symptoms not 
explained by anatomical imaging.7
Historically described as cardiac syndrome X, 
the term coronary microvascular dysfunction 
(CMD) is used to describe abnormalities that result 
in microvascular angina (MVA). CMD is classified 
into five groups (table 1).8 The pathophysiology of 
CMD involves functional and/or structural abnor-
malities in the coronary microcirculation. MVA is 
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prognostically important, and given the challenges in diagnosing 
and treating this problem in daily clinical practice, it is a condi-
tion of unmet need.9
Pathophysiology of the coronary circulation
Epicardial arteries (diameter >500 µm) are predominantly 
capacitance vessels and offer little resistance to flow in the 
healthy state. The coronary microvasculature governs resistance 
to myocardial perfusion. Coronary prearterioles and arterioles 
(vessels <500 µm) contribute approximately 25% and 50% of 
coronary resistance, respectively, in response to flow, stretch 
and metabolic stimuli.10 Myocardial ischaemia may result from 
pathophysiological processes affecting the epicardial conduit 
artery, the microvasculature or both (figure 2).
Aetiology
Cardiovascular risk factors, notably hypertension, are prevalent 
in patients with INOCA. Hypertension is a cause and conse-
quence of endothelial dysfunction, atherosclerosis, microvas-
cular remodelling, rarefaction and interstitial fibrosis. Obesity 
and cigarette smoking may also be relevant. Importantly, many 
patients with INOCA do not have risk factors for vascular 
disease. In these patients, the aetiology may involve a genetic 
abnormality, perturbations in neuroendocrine function (e.g.dys-
regulation of the endothelin system), autonomic nervous system 
abnormalities, or natural changes, such as the menopause.3 
Finally, since the natural history of disease is rarely static, the 
duration and evolution (progression or remission) of disease and 
ageing are also relevant considerations.
Anatomical abnormalities in the coronary circulation
In addition to evidence-based management of obstructive athero-
sclerotic CAD,4 other structural coronary problems (including 
anomalous coronary vessels, coronary artery fistula, certain 
coronary artery bridges or aneurysms) should be considered.
Coronary microvascular disease may reflect anatomical abnor-
malities including microvascular remodelling (ie, reductions in 
capillary luminal size) and number (ie, rarefaction), and there-
fore increased microvascular resistance to myocardial blood flow 
(Poiseuille’s law). Angina may result from systemic disorders, 
such as hypertension, or myocardial pathology such as hyper-
trophic cardiomyopathy, which involves remodelling of intra-
mural coronary arterioles, vascular rarefaction and perivascular 
fibrosis.11
In vivo, the diagnosis of anatomical changes in coronary small 
vessels is challenging. Yamamoto et al12 performed endomyo-
cardial biopsy in 11 patients with angina and no angiographic 
obstructive CAD, and demonstrated cardiomyocyte hypertrophy 
and replacement fibrosis compared with a control population. 
Osamichi et al13 undertook endomyocardial biopsy in 24 patients 
with MVA and demonstrated smooth muscle cell hypertrophy 
and narrowed microvasculature due to basement membrane 
thickening. In contrast, Richardson et al14 performed endo-
myocardial biopsy in seven patients with invasively diagnosed 
MVA and found no significant morphological abnormality.
Functional microvascular abnormalities
Functional abnormalities of the epicardial arteries and microves-
sels relate to (1) enhanced vasoconstriction, (2) impaired 
vasodilation secondary to endothelium-independent or endo-
thelium-dependent mechanisms, or (3) a combination of these 
problems. Disorders of coronary vasomotion include epicardial 
and/or microvascular coronary spasm, impaired coronary artery 
vasorelaxation and endothelial dysfunction-related reduced 
myocardial blood flow.15 Various vasoactive substances maybe 
implicated. For example, endothelin-1 (ET-1) concentrations 
are elevated in patients with primary CMD; in 1034 patients 
who underwent stress positron emission tomography (PET) 
imaging for the investigation of angina, Johnson et al16 identified 
abnormal diffuse heterogeneous myocardial perfusion that was 
associated with CMD. In an animal model, this abnormal perfu-
sion pattern was recreated using intracoronary infusions of ET-1, 
implying that ET-1 contributes to abnormal vasoconstriction in 
patients with CMD.17
The coronary endothelium regulates vascular tone and 
myocardial blood flow via nitric oxide (NO)-dependent mech-
anisms.10 Abnormal vasoconstrictive responses to acetylcholine 
infusion, consistent with impaired endothelial function, occur 
in patients with angina and non-obstructive epicardial CAD.15 
Abnormal endothelium-independent vasodilator function may 
involve resistance to NO, adenosine and prostacyclin.18
Angina-myocardial ischaemia discordance and propensity to 
ischaemia
The ‘ischaemic threshold’ (the heart rate–blood pressure 
product at the onset of angina or ECG changes) differs between 
individuals.19 Innate variations in neurogenic vascular tone and 
endocrine changes (eg, menopause) dictate the propensity to 
vasospasm while environmental factors including cold tempera-
ture, exertion and mental stress are relevant.20
Silent ischaemia is common and prognostically important.21 
Interestingly, the large US CLARIFY registry highlighted 
the importance of symptoms, showing that angina with 
or without concomitant ischaemia was more predictive 
of adverse cardiac events compared with silent ischaemia 
alone.22 Variations in pain thresholds and cardiac innervation 
Figure 1 Hierarchical nomenclature of coronary artery disease 
endotypes that cause ischaemic heart disease. Modified with 
permission.2 CAD, coronary artery disease; INOCA, ischaemia and no 
obstructive coronary artery disease; MINOCA, myocardial infarction with 
no obstructive coronary artery disease. 
table 1 Classification of coronary microvascular dysfunction
coronary 
microvascular 
dysfunction (cMd)
Type 1 Primary CMD in the absence of underlying myocardial 
disease or obstructive epicardial CAD
Type 2 CMD in the presence of myocardial disease (eg, 
hypertrophic cardiomyopathy, hypertensive heart disease)
Type 3 CMD in the presence of obstructive CAD (either stable 
CAD or acute coronary syndrome)
Type 4 Iatrogenic CMD secondary to myocardial revascularisation
Type 5 CMD following cardiac transplantation
CAD, coronary artery disease.
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and diabetic neuropathy are all potential mechanisms for the 
discordance between symptoms and ischaemia.23 Patients 
with MVA may have abnormal adrenergic function, increased 
painful sensitivity to innocuous cardiac stimuli (eg, radio-
graphic contrast), and a lower pain threshold and tolerance 
to the algogenic effects of adenosine (thought to be the main 
effector of ischaemia-mediated chest pain).24 25
Advances in the diagnosis of disorders of coronary artery 
function
Coronary angiography has a resolution of 500 µm and the 
microvasculature is not visible on CT or invasive angiography. 
Myocardial biopsy is not a feasible diagnostic option. Therefore, 
currently, the diagnosis of CMD is empirical when specific tests 
of coronary function are not used (figure 3).
Non-invasive assessment of coronary artery function
Microvascular disease may be a generalised process resulting 
in diffuse myocardial perfusion abnormalities. Therefore, 
traditional non-invasive ischaemia tests may be normal in 
patients with CMD due to the absence of regional perfusion 
abnormalities typically seen in obstructive CAD. Myocardial 
perfusion scintigraphy has comparatively low spatial resolu-
tion (~1×1 cm per pixel), and is thus relatively insensitive 
for detection of subtle perfusion abnormalities secondary 
to microvascular dysfunction. Stress transthoracic Doppler 
echocardiography (TTDE) is typically performed in the left 
anterior descending, and is a potentially feasible and cheap 
method of assessing flow velocity at rest and during maximal 
hyperaemia to estimate coronary flow reserve (CFR); 
however, TTDE lacks accuracy and does not interrogate all 
myocardial segments.26
The reference-standard non-invasive assessment of myocar-
dial blood flow is stress PET imaging, which permits quantitative 
flow derivation in mL/g/min. Clinically, PET-derived quanti-
fication of myocardial blood flowcan assist in the diagnosis of 
diffuse and impaired CFR, which is associated with increased 
risk of major adverse cardiac events (MACE).27 In real-world 
practice, the use of PET is limited by its availability (including 
radioisotopes), cost and exposure to ionising radiation.
Cardiac magnetic resonance (CMR) imaging holds 
most promise as a preferred non-invasive imaging option. 
Although CMR is also comparatively expensive, it has clear 
benefits, including lack of ionising radiation, high spatial 
resolution (ie, ~2.5×2.5 mm at 1.5 Tesla, ~1 ×1 mm at 
3.0 Tesla), high sensitivity and specificity for perfusion 
abnormalities, and multiparametric imaging techniques 
(reference-standard left ventricular volumes and function, 
myocardial tissue characterisation with late gadolinium 
enhancement imaging and parametric mapping). Panting 
et al28 demonstrated the qualitative detection of inducible 
circumferential subendocardial perfusion defects in patients 
with syndrome X. Semiquantitative assessment of CFR (the 
myocardial perfusion reserve index, MPRi) from CMR has 
been shown to predict abnormal response to invasive coro-
nary reactivity testing, and is an important prognosticator in 
a large natural history study of women with non-obstructive 
CAD.29 Novel pixel-wise absolute perfusion quantification 
of myocardial perfusion by CMR will likely improve the 
efficiency of absolute quantification of myocardial blood 
flow by CMR.30
Invasive guidewire-based techniques
Invasive tests of coronary artery function are the reference stan-
dard for the diagnosis of CMD.31 We contend that a complete 
diagnostic evaluation of the coronary circulation should assess 
structural and functional pathology. Pressure-derived indices, 
such as fractional flow reserve (FFR), contrast-enhanced FFR, 
Figure 2 Structural and functional disorders of the coronary circulation. CFR, coronary flow reserve; FFR, fractional flow reserve; IMR, index of 
microcirculatory resistance; HMR, hyperaemic microvascular resistance; ACh, Acetycholine; LVH, left ventricular hypertrophy
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instantaneous wave-free ratio (iFR) and resting Pd/Pa, are useful 
tests to guide revascularisation decisions.32 However, as is the 
case with coronary angiography, these indices do not inform 
the clinician about microvascular resistance and or vasodilator 
potential.
CFR reflects the ratio of hyperaemic flow to basal flow and was 
first described by Gould et al in 1974.33 Microvascular resistance 
may be measured by thermodilution (index of microcirculatory 
resistance, IMR)34 or Doppler (hyperaemic microvascular resis-
tance, HMR).35 CFR and IMR/HMR reflect distinct properties 
of vascular (dys)function and discordance (normal/abnormal) is 
common.36 CFR reflects the combined vasodilator capacity of 
the epicardial coronary artery and its subtended microvascula-
ture. There are some limitations to using invasively measured 
CFR in isolation due to its sensitivity to systemic haemody-
namics, myocardial contractility and challenges with establishing 
true resting coronary blood flow during invasive coronary angi-
ography. Specific measures of microvascular resistance (i.e., 
IMR and HMR) are more reproducible, specific and are directly 
informative about microvascular disease.37
Sezer et al38 assessed coronary physiology in patients with 
diabetes with INOCA, showing that early reduction in CFR was 
driven by disturbed coronary regulation and high resting flow. 
In long-standing diabetes, elevated microvascular resistance may 
reflect structural remodelling of small vessels. This process paral-
lels the paradox of microvascular disease in diabetic nephrop-
athy where increased glomerular filtration rate (GFR) typifies 
the early stages of disease prior to later structural damage and 
reduction in GFR.
Functional disorders of coronary vasomotion
FFR, CFR and IMR are typically derived using intravenous 
adenosine, which is an endothelium-independent vasodi-
lator. Assessment of coronary endothelial function has distinct 
prognostic utility.39 Abnormal flow response to endothelial 
agonist can be assessed using symptoms and angiography alone 
(ie, >20% angiographic reduction in coronary luminal diameter 
during acetylcholine infusion),31 intracoronary Doppler flow 
measurement or with thermodilution. Acetylcholine may be 
used at higher bolus doses (eg, 100–200 µg) in a provocation 
test to detect abnormal coronary vasoreactivity (ie, vasospasm). 
A consensus document by the Coronary Vasomotion Disorders 
International Study Group (COVADIS) defines the criteria for 
a positive provocative test as meeting the following criteria: (1) 
reproduction of the usual chest pain, (2) ischaemic ECG changes 
and (3) >90% vasoconstriction on angiography40 (figure 4).
recent clInIcAl evIdence
detection and incidence
Lee et al prospectively enrolled 139 consecutive patients in a 
single-centre study with angina and no obstructive CAD. During 
comprehensive invasive multimodality assessment at angiography, 
all patients had atherosclerosis on intravascular ultrasound, 21% 
had abnormal IMR, 44% had endothelial dysfunction and only 
23% had no explanation for their symptoms.41 Coronary vasore-
activity testing with acetylcholine is generally safe and useful for 
the detection of epicardial and/or microvascular spasm.15 The 
prevalence of microvascular spasm and vasospastic angina (VSA) 
is not fully resolved, but these conditions may occur in up to 
two-thirds of patients with a ‘negative’ angiogram.42
Coronary atherosclerosis and abnormal vasomotion are 
inextricably linked. A Korean study of CFR and IMR in angi-
ographically moderate epicardial lesions demonstrated around 
Figure 3 Clinical case demonstrating the utility of non-invasive 
and invasive diagnostic tests for coronary artery function. A 73-year-
old woman presented with a 2-year history of typical Canadian 
cardiovascular society (CCS) class 2 angina. The patient had type 
2 diabetes mellitus, an elevated body mass index and had previously 
been documented to have a normal invasive coronary angiogram 8 
years previously. Invasive coronary angiography (A,B) demonstrated 
unobstructed epicardial coronary arteries. In the left anterior descending 
artery, the fractional flow reserve (FFR) value was 0.95, consistent with 
no epicardial flow-limiting stenosis (C). The coronary flow reserve (CFR) 
was reduced (1.3, normal >2.0), and the index of microcirculatory 
resistance (IMR) was elevated (33 units, normal <25), indicative of 
impaired epicardial and microvascular vasodilation and increased 
microvascular resistance respectively (C). Coronary endothelial function 
assessment using graded intracoronary acetylcholine infusion revealed 
mild vasoconstriction (dashed line) consistent with endothelial 
dysfunction (D) compared with endothelial-independent function testing 
with intracoronary glyceryl trinitrate (E). There was inducible coronary 
vasospasm using 100 µg acetylcholine bolus over 20 s (not shown). The 
patient subsequently underwent adenosine stress perfusion CMR, which 
demonstrated an inducible circumferential subendocardial perfusion 
defect in the basal short axis slice (arrows) with adenosine stress 
(F), compared with the corresponding rest perfusion imaging (G). A 
pixel-wide fully quantitative myocardial blood flow analysis confirmed 
markedly reduced myocardial blood flow in the subendocardium with 
adenosine stress (H) compared with the corresponding rest perfusion 
image (I). A diagnosis of coronary microvascular dysfunction was made. 
The patient was symptomatically improved at 3-month follow-up after 
treatment with nebivolol, statin and ACE inhibitors was started. The 
CMR methods were provided by Andrew Arai and Li-Yueh Hsu, National 
Institutes of Health, MD.
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Figure 4 Schematic illustration of the diagnostic work-up for SCS following exclusion of obstructive epicardial CAD. (1) Non-invasive diagnostic 
testing with multiparametric stress perfusion CMR imaging assessment demonstrating pixel-wide fully quantitative myocardial blood flow analysis 
from cardiac base to apex, cine imaging, native T1 parametric mapping and late gadolinium enhancement imaging. (2) Invasive diagnostic testing 
with (A) dual pressure-sensitive and temperature-sensitive coronary wire or coronary Doppler and pressure-sensitive wire, and (B) endothelial and 
vasospastic testing with intracoronary acetylcholine. CAD, coronary artery disease; CFR, coronary flow reserve; CMR, cardiac magnetic resonance; 
FFR, fractional flow reserve; HMR, hyperaemic microvascular resistance; iFR, instantaneous wave-free ratio; IMR, index of microcirculatory resistance; 
PET, positron emission tomography; SCS, stable coronary artery syndrome; TTDE, transthoracic Doppler echocardiography.
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a quarter of 516 coronary arteries had an elevated IMR and a 
similar proportion had reduced CFR (<2.0).36 Both low CFR 
with elevated IMR were associated with poor prognosis.
Prognosis of patients and no obstructive cAd
The prognosis of SCS is linked with the underlying pathophys-
iological mechanism and varies depending on the population 
studied.9 Patients with angiographically normal coronaries and 
only exercise-induced symptoms may be in a better prognostic 
group.43 Data from the Women’s Ischemia Syndrome Evalua-
tion (WISE) study suggests that there is a worse prognosis; the 
5-year annualised risk of MACE was 16.0% in women with 
non-obstructive CAD, 7.9% in women with normal coronary 
arteries and 2.4% in an asymptomatic control group (p≤0.002 
after adjustment for baseline cardiovascular risk).9 Similarly, 
a Danish cohort study of 11 223 patients with angina found 
an increased risk of MACE for patients with diffuse non-ob-
structive CAD and those with normal coronaries (adjusted HR 
of 1.85 and 1.52, respectively), compared with a reference 
population.
therapy
Pharmacological symptomatic therapy
A detailed review of therapy for the different disorders of 
coronary artery function is beyond the scope of this review.44 
A summary of currently available therapies aligning with 
the different SCS disease endotypes is shown in table 2 (see 
additional references in online supplementary file 1). Robust 
evidence for the treatment of SCS is lacking. The treatment 
effect in many studies is potentially diluted by enrolment of 
heterogeneous groups of patients with distinct pathophysio-
logical mechanisms of CMD that may respond differently to 
specific treatment modalities. Current European Society of 
Cardiology (ESC) guidelines provide recommendations for 
patients with CMD suggesting ß-blockers as first-line therapy, 
with calcium antagonists recommended if the former is not 
tolerated or efficacious.4 Unlike in patients with angina and 
obstructive CAD, nitrates are not generally effective for 
treating SCS due to CMD.45 In a randomised, placebo-con-
trolled clinical trial of ranolazine led by the WISE investiga-
tors, although there were no overall improvements in angina 
and MPRi with ranolazine, benefit was observed in the 
subgroup of patients with a reduced CFR (<2.5) at baseline.46 
Patients with VSA may benefit symptomatically from treat-
ment with both nitrate and calcium channel antagonists while 
the latter may have prognostic benefit.47 Rho-kinase inhibitors 
and endothelin-receptor antagonists represent potential future 
therapeutic options.
Secondary prevention
ESC guidelines support the use of secondary prevention with 
aspirin and statin therapy.4 In contrast, the UK National Insti-
tute for Health and Care Excellence guideline-95 on manage-
ment of stable angina cites the enigmatic term ‘Syndrome X’, 
but guidance on the diagnosis and management is limited, 
reflecting the limited evidence base.48 Contemporary guide-
lines should be followed for the management of vascular risk 
factors in patients with INOCA.3 41 In patients with CMD, 
statin therapy reduces ischaemia as revealed by reduced 
ST-segment deviation following exercise testing and improves 
exercise capacity and flow-mediated dilatation in the brachial 
artery in patients with CMD.49 ACE inhibitors (ACEi) improve 
endothelial dysfunction and vasoreactivity via NO stimulation 
helping to reverse vascular hypertrophy and improve vascular 
compliance.
Non-pharmacological therapy
Lifestyle measures promote well-being in patients with INOCA 
through smoking cessation, healthy eating (eg, Mediterra-
nean diet) and physical activity.3 The Comprehensive Treat-
ment of Angina in Women With Microvascular Dysfunction 
trial (NCT02910154) will randomise women with angina and 
CMD to comprehensive multimodality intervention (dietary, 
exercise, and statin and ACEi therapy) or control therapy to 
determine whether angina and microvascular dysfunction can 
be improved.
Future directions
Overall, there is a critical missing link between the use of rele-
vant diagnostic tests of coronary artery function, therapeutic 
agents with proven efficacy and health outcomes of patients 
with angina without obstructive CAD. This gap in evidence 
is currently being addressed in the British Heart Foundation 
CORonary MICrovascular Angina randomised controlled 
trial (CorMicA NCT03193294). A personalised approach to 
therapy is desirable and it is reasonable to target those patients 
with impairment of microvascular dilation characterised by 
reduced CFR with anti-anginals that reduce heart rate and 
oxygen consumption (eg, ß-blockers), whereas vasodilators or 
ACEi would be more appropriate for patients with evidence of 
in microvascular constriction.50 
‘Stable coronary syndrome’ reflects a disease-based, clin-
ically relevant classification that reflects the interaction 
between structural and functional disorders throughout the 
coronary circulation. The paucity of pathway-specific therapy 
presents an opportunity for novel research using stratified 
medicine. Our vision is for a personalised medicine approach 
whereby SCS endotypes, defined by the results of coronary 
function tests, may benefit from targeted therapy. Further 
research is needed to determine whether this paradigm may 
lead to patient benefits (table 3).
table 3 Proposed comprehensive research strands for patients with 
ischaemia and no obstructive coronary artery disease (INOCA)
comprehensive 
InocA research 
strands
Stratified medicine trials  ► Diagnostic tests (rule-in/rule-out)
 ► Stratification of endotypes for evidence-based therapy
Vascular science  ► Investigations of disease mechanisms, for example, 
endothelial dysfunction and dysregulation of the 
endothelin system
Imaging and modelling  ► Clinical trials of quantitative perfusion CMR 
versus standard methods
 ► Patient-specific computed models of disease to predict 
responses to novel therapeutics
Molecular pathology 
and vascular 
histopathology
 ► Protein assay-based scores and genetic variants are 
potential biomarkers for disorders of coronary function.
 ► Identification of drug targets
Therapeutic trials  ► Enhanced system antagonists
 ► Vasodilating ß-blockers
 ► Lifestyle interventions, for example, exercise, 
weight loss
Health informatics and 
value assessments
 ► Assess the cost-effectiveness of innovative stratified 
approaches
Patient and public 
involvement
 ► Ensures relevance of research to patients and carers
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